Boehringer Ingelheim's Respimat Inhaler Awarded Arthritis Foundation's Ease of Use Commendation

Wednesday, January 10, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

- Respimat is the first and only inhaler acknowledged by the Arthritis Foundation as easy-to-use for people with arthritis

RIDGEFIELD, Conn., Jan. 10, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the Arthritis Foundation

recognized Respimat with its Ease of Use Commendation. As defined by the Arthritis Foundation, the Ease of Use Commendation, is awarded to "products proven to make life easier for people with arthritis and other physical limitations."

"The Arthritis Foundation awards its Ease of Use Commendation when a product's design or packaging has been proven to make taking medication easy and comfortable for people living with arthritis," said Cindy McDaniel, Senior Vice President, Consumer Health, Arthritis Foundation. "To earn this Commendation, the Respimat inhaler went through a series of evaluations from experts and people living with arthritis."

The Respimat inhaler was designed to deliver the medication through a slow-moving mist, which gets medicine deep into patients' lungs. The slow-moving mist of the Respimat inhaler provides patients with enough time to breathe in the medication.

In addition, the Respimat inhaler operates independent of inspiratory effort, helping patients effectively breathe the medicine into their lungs without having to sharply inhale the medicine. As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as coordination between actuation of the inhaler and inspiration through the delivery system. The duration of inhalation should be at least as long as the spray duration (1.5 seconds).

To earn the Ease of Use Commendation, the Respimat inhaler was independently tested by experts at the Intuitive Design Applied Research Institute lab in Atlanta and evaluated by people with arthritis.

"We are proud of our Respimat inhaler as being the first and only inhaler recognized by the Arthritis Foundation as easy-to-use for everyone," said Jean-Michel Boers, president, Human Pharma, Boehringer Ingelheim Pharmaceuticals, Inc. "For nearly a century, we have been committed to advancing care for serious respiratory diseases, and the Respimat inhaler is an important achievement as part of this long-standing commitment."

Boehringer Ingelheim's Respimat family of products includes four FDA-approved medicines for COPD as well as one for asthma.

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 145 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2015, Boehringer Ingelheim achieved net sales of about $15.8 billion (14.8 billion euros). R&D expenditure corresponds to 20.3 percent of its net sales.

For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.

Media ContactChris WahlersAssociate Director, Communications, Primary Care Boehringer Ingelheim Pharmaceuticals, Inc.Ridgefield, Connecticut 06877christopher.wahlers@boehringer-ingelheim.com C: 202.798.4375

 

Cision View original content:http://www.prnewswire.com/news-releases/boehringer-ingelheims-respimat-inhaler-awarded-arthritis-foundations-ease-of-use-commendation-300580371.html

SOURCE Boehringer Ingelheim



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store